Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals Inc (NQ: AVIR )

3.000 -0.050 (-1.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 857,713
Open 2.990
Bid (Size) 2.910 (4)
Ask (Size) 3.190 (27)
Prev. Close 3.050
Today's Range 2.940 - 3.075
52wk Range 2.940 - 9.790
Shares Outstanding 83,341,574
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
-37.63%
-37.63%
1 Month
-24.81%
-24.81%
3 Month
-34.64%
-34.64%
6 Month
-48.28%
-48.28%
1 Year
-58.79%
-58.79%

More News

Read More
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Preview: Atea Pharmaceuticals's Earnings
Via Benzinga
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
Via Benzinga
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
Via Benzinga
Recap: Atea Pharmaceuticals Q2 Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Short Volatility Alert: Atea Pharmaceuticals
Via Benzinga
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals Earnings Preview
Via Benzinga
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Via Investor's Business Daily
Stocks Selling For Less Than Cash Per Share
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.